Zhou Shan Shi

Researchers are observing patients who receive Siltartoxatug Injection, also known as Sintetol4, to prevent tetanus following injury. This large-sample, real-world registry aims to document injury and wound conditions and evaluate clinical outcomes related to tetanus prevention. The study focuses on collecting safety information and any adverse reactions after receiving the injection. Participants in this observational study receive Siltartoxatug Injection as part of their tetanus prophylaxis after injury. The study does not involve randomization or comparison groups but follows patients over time to monitor outcomes. A key part of the study is the follow-up at 90 days after administration to assess whether tetanus develops and to record any safety events. During the study, patient injury details and wound conditions will be carefully noted. Safety data will be selectively collected to identify any adverse reactions or serious events linked to Siltartoxatug use. The main outcome measure is the occurrence of tetanus within 90 days post-injection. Participants are followed for this 90-day period to evaluate treatment outcomes and safety.

People with end stage kidney disease ESKD who require dialysis face a much higher risk of cardiovascular disease compared to the general population, with cardiac issues causing 58% of deaths in this group. However, while aspirin is known to reduce cardiovascular problems in the general population, there is limited evidence about its effects in dialysis patients. The ASPIrin to Reduce Event in Dialysis ASPIRED trial aims to study whether taking low-dose aspirin can safely improve cardiovascular outcomes in people with ESKD receiving dialysis. This study is a multi-center, double-blind, randomized controlled trial that will compare daily low-dose aspirin 100 mg to a placebo pill in patients undergoing dialysis. The trial uses an existing dialysis registry platform to screen, recruit, and collect data during routine clinical care, minimizing participant burden and study costs. Randomization is managed through a secure web-based system, and follow-up visits occur every six months as part of regular clinic visits. The trial is expected to last approximately five years and includes oversight by an independent safety and monitoring board. Participants will be involved in regular six-monthly clinic visits where their health will be monitored as part of their usual dialysis care. Researchers will track the occurrence of major cardiovascular events, including heart attacks, strokes, vascular complications, and deaths, throughout the study period. Data will be collected from routine clinical procedures and the dialysis registry to evaluate outcomes. Safety and efficacy will be closely monitored, and the study will follow participants for up to five years to assess the long-term effects of aspirin use in this population.

Researchers are conducting a multicenter, single-blind, randomized controlled trial to evaluate the safety and effectiveness of combined interventions for sarcopenia, a condition characterized by loss of muscle mass and strength. Participants who meet the diagnostic criteria for sarcopenia and are 30 years or older are included. The trial compares routine interventions alone and in combination with supplements to assess their impact on muscle health and physical function. Participants are divided into three groups a control group receiving routine care including nutritional guidance, progressive resistance exercise, safety advice, and treatment for complications over 24 weeks an experimental group 1 receiving the same routine care plus whey protein powder supplementation for 12 weeks at 60 grams per day in three doses and an experimental group 2 receiving routine care along with both whey protein powder and eldecalcitol capsules at 0.75 micrograms daily for 12 weeks. Liver and kidney function are monitored to adjust protein dosage if needed. Throughout the 24-week study, participants undergo regular assessments including general health evaluations, blood tests, muscle mass and strength measurements, and physical function tests like grip strength and 6-meter walking speed. Researchers also monitor adverse events to evaluate safety. The main outcome is muscle mass change, with secondary outcomes including muscle strength, walking speed, and incidence of adverse reactions.

Researchers are evaluating whether the combination of Bailing Capsules and Guben Kechuan Granules can help treat adults with stable bronchiectasis. This study also aims to determine the safety of these combined treatments compared to the standard Western medical treatment. The main questions focus on whether this combination reduces the number of acute exacerbations in patients with stable bronchiectasis. Participants in the experimental group will take Bailing Capsules orally four capsules three times a day plus Guben Kechuan Granules one bag three times a day alongside standard Western medical treatment for 24 weeks. The control group will receive only the standard Western medical treatment. Both groups will be monitored throughout the study period, which includes visits at weeks 4, 12, 24, and 48, with symptom diaries kept by participants. During the study, participants will visit the clinic for checkups and tests to assess lung function at 12, 24, and 48 weeks. Researchers will measure the number of acute exacerbations during treatment and follow-up periods at 24 and 48 weeks. Safety and treatment adherence will be monitored throughout the trial, which lasts for nearly a year, allowing a comprehensive evaluation of treatment effects and patient health.

This research aims to evaluate the safety and effectiveness of TQA2225AP025, a recombinant human FGF21-Fc fusion protein, in adults with Non-Alcoholic Steatohepatitis NASH. It is a randomized, double-blind, placebo-controlled Phase II study designed to assess how well two different doses of this treatment work in managing NASH, a liver condition characterized by fat buildup and inflammation. Participants will receive either 25mg or 50mg of TQA2225AP025 or a matching placebo, given by weekly subcutaneous injections for 48 weeks. The study includes two experimental groups receiving the different doses, and all treatments are administered under blinded conditions to assess the treatment effects accurately. During the study, participants will undergo liver biopsies at the start and after 48 weeks to measure changes in liver condition using the NASH CRN scoring system. Safety will be closely monitored by tracking any adverse events throughout the treatment period. The study is expected to provide detailed information on both the treatment impact on liver health and its safety profile over nearly a year of participation.